<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852024000200003</article-id>
<article-id pub-id-type="doi">10.48193/pzbbwq92</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[PET-CT 18F-PSMA 1007 in the staging of patients with prostate cancer prior to curative intent radiotherapy: a prospective observational study]]></article-title>
<article-title xml:lang="es"><![CDATA[PET-TC 18F-PSMA 1007 en la estadificación de pacientes con cáncer de próstata previo a la radioterapia con intención curativa: un estudio observacional prospectivo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Modina]]></surname>
<given-names><![CDATA[Patricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Lucas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arceluz]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero Acuña]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Faccio]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bergero]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Sanatorio Privado San Gerónimo  ]]></institution>
<addr-line><![CDATA[ Santa Fe]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<volume>84</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852024000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852024000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852024000200003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: The objective of our study was to assess whether there are staging changes in CaP with PET PSMA compared to standard diagnostic methods, and if these changes occurred, to understand how they altered the treatment of patients with an initial diagnosis of CaP and their relationship with the D'amico score.  Methods: We present a prospective observational study conducted on patients initially diagnosed with prostate cancer, who underwent standard staging studies alongside PET PSMA imaging.  Results: Forty patients diagnosed with prostate cancer were staged using standard diagnostic methods and PET PSMA. In 40% of the patients, initial staging changed based on the results obtained from PET PSMA. After PET PSMA, the uro-oncology committee decided to modify the initial treatment plan in 27.5% of the cases, including radiation boost targeting the extra-prostatic lesions detected by PET PSMA. When correlating the change in staging with PET PSMA versus the D'amico risk score, no changes were observed in the low-risk group, 19% in the intermediate-risk group, and 62% in the high-risk group. These differences were statistically significant (X2=9.2; df=2; p=0.01).  Limitation and value: The study faced limitations in sample size and lack of long-term patient follow-up. However, it highlights key contributions: the promising evaluation of PET PSMA in staging, its influence on therapeutic decisions, and its association with the D'amico score.  Conclusion: PET PSMA showed substantial changes in CaP staging, particularly in higher-risk patients, suggesting its potential utility in guiding therapeutic decisions before radiotherapy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  El objetivo de nuestro estudio fue evaluar si existen cambios de estadificación en CaP con PET PSMA en comparación con los métodos diagnósticos estándar, y si estos cambios ocurrieron, comprender cómo alteraron el tratamiento de los pacientes con diagnóstico inicial de CaP y su relación. con la partitura de D'amico.  Métodos:  Presentamos un estudio observacional prospectivo realizado en pacientes con diagnóstico inicial de cáncer de próstata, a quienes se les realizaron estudios de estadificación estándar junto con imágenes PET PSMA.  Resultados:  Cuarenta pacientes diagnosticados con cáncer de próstata fueron estadificados utilizando métodos de diagnóstico estándar y PET PSMA. En el 40 % de los pacientes la estadificación inicial cambió en función de los resultados obtenidos de la PET PSMA. Después del PET PSMA, el comité de urooncología decidió modificar el plan de tratamiento inicial en el 27.5 % de los casos, incluyendo un refuerzo de radiación dirigido a las lesiones extraprostáticas detectadas por el PET PSMA. Al correlacionar el cambio en la estadificación con PET PSMA versus la puntuación de riesgo de D'amico, no se observaron cambios en el grupo de bajo riesgo, el 19 % en el grupo de riesgo intermedio y el 62 % en el grupo de alto riesgo. Estas diferencias fueron estadísticamente significativas (X2=9,2; gl=2; p=0,01).  Limitación y valor:  el estudio enfrentó limitaciones en el tamaño de la muestra y falta de seguimiento de los pacientes a largo plazo. Sin embargo, destaca contribuciones clave: la prometedora evaluación de PET PSMA en la estadificación, su influencia en las decisiones terapéuticas y su asociación con la puntuación de D'amico.  Conclusión:  PET PSMA mostró cambios sustanciales en la estadificación de CaP, particularmente en pacientes de mayor riesgo, lo que sugiere su utilidad potencial para guiar las decisiones terapéuticas antes de la radioterapia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[PSMA]]></kwd>
<kwd lng="en"><![CDATA[PET-CT]]></kwd>
<kwd lng="en"><![CDATA[tomography]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[PSMA]]></kwd>
<kwd lng="es"><![CDATA[PET-CT]]></kwd>
<kwd lng="es"><![CDATA[tomografía]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lortet-Tieulent]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics, 2012]]></article-title>
<source><![CDATA[CA: a cancer journal for clinicians]]></source>
<year>2015</year>
<volume>65</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>87-108</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Culp]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Efstathiou]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2020</year>
<volume>77</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrentschuk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vela]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<numero>10231</numero>
<issue>10231</issue>
<page-range>1208-16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwarzenboeck]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Rauscher]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bluemel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fendler]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Pomper]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSMA Ligands for PET Imaging of Prostate Cancer]]></article-title>
<source><![CDATA[Journal of Nuclear Medicine]]></source>
<year>2017</year>
<volume>58</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1545-52</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&#8217;Amico]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1998</year>
<volume>280</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>969</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Kalmthout]]></surname>
<given-names><![CDATA[LWM]]></given-names>
</name>
<name>
<surname><![CDATA[Van Melick]]></surname>
<given-names><![CDATA[HHE]]></given-names>
</name>
<name>
<surname><![CDATA[Lavalaye]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Kooistra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Klerk]]></surname>
<given-names><![CDATA[JMH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2020</year>
<volume>203</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>537-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
